Beyond BCG: the potential for a more effective TB vaccine

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• The Bacille Calmette-Guerin (BCG) vaccine has been a global standard for tuberculosis (TB) prevention for decades.
• Despite its widespread use, safety, and low cost, concerns regarding BCG's waning effectiveness are growing.
• Rising TB rates, exacerbated by the AIDS epidemic and multidrug-resistant strains, highlight the urgent need for improved TB control strategies.

Purpose of the Study:

• To review the current status of the BCG vaccine and the challenges associated with its effectiveness.
• To explore promising new-generation TB vaccine candidates currently under development.
• To discuss the future prospects of TB vaccination, including the potential replacement or enhancement of BCG.

Main Methods:

• Literature review of existing studies on BCG vaccine efficacy and new TB vaccine development.
• Analysis of current tuberculosis epidemiology, including drug-resistant strains and co-infection with HIV.
• Synthesis of information on novel vaccine platforms such as DNA, recombinant, auxotrophic, and subunit vaccines.

Main Results:

• The BCG vaccine, while safe and affordable, exhibits variable and often limited long-term protection against tuberculosis.
• Emerging TB strains, particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) forms, pose significant challenges to existing control measures.
• Several novel TB vaccine candidates, including DNA, recombinant, and subunit vaccines, show promise in preclinical and early clinical studies.

Conclusions:

• The limitations of the BCG vaccine necessitate the development of more effective alternatives.
• New TB vaccine candidates offer potential for improved and broader protection against tuberculosis.
• Clinical trials will be crucial in determining whether new vaccines will replace BCG or be used as adjuncts to boost BCG-induced immunity.